ArticlePharmaceuticals (Basel, Switzerland)2024
Synthesis of New Thiazole-Privileged Chalcones as Tubulin Polymerization Inhibitors with Potential Anticancer Activities.
Article in Pharmaceuticals (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Therapeutic potential of chalcone-1,2,3-triazole hybrids as anti-tumour agents: a systematic review and SAR studies.Future medicinal chemistry · 2025Pooled it
- Medicinal chemistry perspective of chalcone derivatives as anticancer agents: synthetic strategy, biological activity, and structure-activity relationship.Molecular diversity · 2026Review
- Article
- Design, synthesis, and antiproliferative activity of novel thiazole-based derivatives as tubulin polymerization inhibitors targeting the colchicine binding site.RSC advances · 2026Article
- A Review of Recent Advances in the Anticancer Mechanisms of Activity of Novel Thiazoles and 4-Thiazolidinones/Thiazolidinediones (2021-2025).Molecules (Basel, Switzerland) · 2026Review
- Discovery of a Novel Coumarin/Thiazole Chalcone Hybrid as a Potent Dual Inhibitor of Tubulin and Carbonic Anhydrases IX & XII with Promising Anti-Proliferative Activity.Molecules (Basel, Switzerland) · 2026Article
- Design, synthesis,RSC advances · 2026Article
- Development of a novel series of thiazole-based compounds with enhanced antiproliferative properties as tubulin polymerization inhibitors.Frontiers in chemistry · 2026Article
- Design, Synthesis, and Mechanistic Study of Novel Ciprofloxacin/Thiazole Chalcone Hybrids as Potential Anticancer Agents.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Current progress of 1,2,3-triazole hybrids as EGFR inhibitors for cancer therapy - a literature review.RSC advances · 2025Review
- Deconstruction of Desacetamidocolchicine's B Ring Reveals a Class 3 Atropisomeric AC Ring with Tubulin Binding Properties.The Journal of organic chemistry · 2025Article
- From Infection to Tumor: Exploring the Therapeutic Potential of Ciprofloxacin Derivatives as Anticancer Agents.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Design, synthesis, and biological investigation of new thiazole-based derivatives as multi-targeted inhibitors endowed with antiproliferative, antioxidant, and antibacterial properties.Frontiers in chemistry · 2025Article
- Design, synthesis,Frontiers in chemistry · 2025Article
- A novel thiazole-sulfonamide hybrid molecule as a promising dual tubulin/carbonic anhydrase IX inhibitor with anticancer activity.Frontiers in chemistry · 2025Article
- Unveiling the Anticancer Potential of a New Ciprofloxacin-Chalcone Hybrid as an Inhibitor of Topoisomerases I & II and Apoptotic Inducer.Molecules (Basel, Switzerland) · 2024Article
- Indole Derivatives: A Versatile Scaffold in Modern Drug Discovery-An Updated Review on Their Multifaceted Therapeutic Applications (2020-2024).Molecules (Basel, Switzerland) · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A series of novel thiazole-based chalcones were evaluated for their anticancer activity as potential tubulin polymerization inhibitors. In vitro anticancer screening for the thiazole derivatives
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.